Abstract
Even though a single high dose administration of intravenous ferric carboxymaltose (FC) is supposed to be effective, it is unknown whether the second dose of FC given one week after the initial dose provides additional benefits. The aim of the present study was to investigate whether two doses of intravenous ferric carboxymaltose is more effective than a single dose of intravenous FC for replenishing iron stores and correction of anemia in patients with iron deficiency.
Highlights
Anemia is defined as a hemoglobin (Hb) concentration less than 13.0 g/dl for men and less than 12.0 g/dl for women who are not pregnant [1]
Ferric carboxymaltose (FC) is a relatively new intravenous iron product approved in many countries for the intravenous treatment of iron deficiency
Patients were allocated into two groups according to the dose of intravenous FC: Group I (n = 367) had received a single dose of FC (1000 mg); whereas Group II (n = 149) had two doses of 1000 mg of FC and the second dose was administered one week after the initial dose
Summary
Anemia is defined as a hemoglobin (Hb) concentration less than 13.0 g/dl for men and less than 12.0 g/dl for women who are not pregnant [1]. Iron treatment can be given as oral and parenteral forms Even though it is an easy, cheap and effective option, oral iron treatment is not fully devoid of side effects which may interfere with the compliance of the patient [3,4]. Ferric carboxymaltose (FC) is a relatively new intravenous iron product approved in many countries for the intravenous treatment of iron deficiency. It can be infused as a single high dose (1,000 mg) in a short interval such as 15 minutes. FC was associated with rapid hematopoietic improve-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Research and Disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
